menu
    • menu
    [{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Agenus"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ GORTEC"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MEN1309","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"OBT076","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for MEN1309

    Menu

    MEN1309

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford Doses First Patient with OBT076 in Phase 1b Trial for Head and Neck Cancers

                            Details : OBT076 is a experimental CD205/Ly75-directed ADC which is currently being evaluated in phase 1 clinical trials for the treatment of Adenoid Cystic Carcinoma of the Head and Neck.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by ...

                            Details : OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in Combination with CPI Balstilimab for patients with advanced solid tumors.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GORTEC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Phase 1b Trial in Collaboration With GORTEC To Investigate OBT076 In Adenoid ...

                            Details : The collaboration aims to investigate OBT076, an ADC utilizing an ImmunoGen toxin in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck. The trial will investigate OBT076 as monotherapy and in sequence with balstilimab.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 19, 2023

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GORTEC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

                            Details : OBT076 (MEN1309) showed preliminary signs of clinical activity as a monotherapy, with objective responses including long lasting stable disease in six patients, in chemotherapy and checkpoint inhibitor (CPI) refractory patients.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Che...

                            Details : Initial data from the Phase 1 dose escalation part of the OBT076 (MEN1309) trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable tolerability profile; recommended dose was defined at 3.0 mg/kg.

                            Brand Name : MEN1309

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 07, 2022

                            Lead Product(s) : MEN1309,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibo...

                            Details : Under the terms of the agreement, OBT will be the sponsor of the combination trial of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab and responsible for operational execution, and Agenus will provide drug supply and scientific support.

                            Brand Name : MEN1309

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 25, 2021

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enab...

                            Details : Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 31, 2020

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth